Cerebral atrophy in Parkinson's disease patients with visual hallucinations

Eur J Neurol. 2007 Jul;14(7):750-6. doi: 10.1111/j.1468-1331.2007.01768.x.

Abstract

Although visual hallucinations (VH) are relatively frequent in Parkinson's disease (PD) patients, their neural substrates are only known from neuropathological and functional magnetic resonance studies. The aim of this study was to investigate possible structural brain changes on MRI in non-demented PD patients with VH using voxel-based morphometry. Eighteen PD patients with VH were compared to 20 patients with PD without VH and 21 healthy controls. Compared with both controls and the non-hallucinating PD group, PD patients with VH had grey matter volume reductions in the lingual gyrus and superior parietal lobe. Structural changes in these areas involved in higher visual processing may be important in understanding the VH and visual deficits in PD patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparkinson Agents / therapeutic use
  • Antipsychotic Agents / therapeutic use
  • Atrophy
  • Cerebral Cortex / pathology*
  • Cerebral Cortex / physiopathology
  • Female
  • Hallucinations / drug therapy
  • Hallucinations / etiology*
  • Hallucinations / pathology
  • Hallucinations / physiopathology
  • Humans
  • Levodopa / therapeutic use
  • Magnetic Resonance Imaging*
  • Male
  • Parietal Lobe / pathology
  • Parietal Lobe / physiopathology
  • Parkinson Disease / drug therapy
  • Parkinson Disease / pathology
  • Parkinson Disease / physiopathology
  • Parkinson Disease / psychology*
  • Severity of Illness Index
  • Temporal Lobe / pathology
  • Temporal Lobe / physiopathology
  • Visual Cortex / pathology
  • Visual Cortex / physiopathology
  • Visual Pathways / pathology
  • Visual Pathways / physiopathology

Substances

  • Antiparkinson Agents
  • Antipsychotic Agents
  • Levodopa